Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer

A composition and drug technology, applied in the directions of drug combinations, active ingredients of hydroxyl compounds, antipyretics, etc., can solve the problem that targeted therapy does not use effective prognostic biomarkers, etc.

Active Publication Date: 2019-04-02
盖伊福斯汀蒙卡姆尼奇欧
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although biomarkers have been validated for breast cancer (HER copy number), lung cancer (EGFR mutation)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0069] The following composition percentages are weight percentages relative to the total weight of the active substance.

[0070] Composition 1a: beta-elemene (30%), lupeol (30%) and 2-hydroxycinnamaldehyde (40%).

[0071] Composition 1b: beta-elemene (30%), lupeyl alcohol (30%) and 2'-benzoyloxycinnamaldehyde (40%).

[0072] Composition 2: beta-elemene (30%), lupeol (30%), 2-hydroxycinnamaldehyde (20%) and 2'-benzoyloxycinnamaldehyde (20%).

[0073] Composition 3a: beta-elemene (50%), lupeol (30%) and 2-hydroxycinnamaldehyde (20%).

[0074] Composition 3b: beta-elemene (50%), lupeol (30%) and 2'-benzoyloxycinnamaldehyde (20%).

[0075] Composition 4a: β-elemene (15%), lupeol (50%), β-sitosterol (25%) and 2-hydroxycinnamaldehyde (10%).

[0076] Composition 4b: β-elemene (15%), lupeol (50%), β-sitosterol (25%) and 2'-benzoyloxycinnamaldehyde (10%).

[0077] Composition 5a: β-elemene (20%), lupeol (20%), β-sitosterol (40%) and 2-hydroxycinnamaldehyde (20%).

[0078] Compos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition, characterized in that it comprises, as an active substance, a combination of beta-elemene, lupeol and a pharmaceutically active agent selected from cinnamaldehyde, 2-hydroxycinnamaldehyde, 2'- benzoyloxycinnamaldehyde, beta-sitosterol, curcumin and the mixtures thereof.

Description

technical field [0001] The present invention relates to pharmaceutical compositions useful as medicaments, in particular for the treatment of cancer, especially hepatocellular carcinoma. Background technique [0002] Effective palliative care of hepatocellular carcinoma (HCC) has long been considered difficult because this type of tumor is often resistant to conventional cytotoxic chemotherapy. Furthermore, aggressive chemotherapy with several nonselective cytotoxic molecules cannot usually be offered to cirrhotic patients with impaired liver function due to the high risk of systemic side effects. [0003] Improved knowledge of the molecular processes involved in tumorigenesis has directed the identification of new targets for the treatment of cancer. Accordingly, new so-called "targeted" therapies are now available in the treatment of HCC and other tumors. They primarily intervene in the transduction of signals (signals that require cell reproduction). The so-called tyro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/015A61K31/045A61K31/11A61K31/12A61K31/216A61K31/575A61K45/06A61P35/00A61K31/56
CPCA61K45/06A61K31/015A61K31/045A61K31/11A61K31/12A61K31/216A61K31/56A61K31/575A61P35/00A61K2300/00A61P29/00A61P1/04
Inventor 盖伊·福斯汀·蒙卡姆·尼奇欧
Owner 盖伊福斯汀蒙卡姆尼奇欧
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com